| Time to onset of bisphosphonate‐related osteonecrosis of the jaws: a multicentre retrospective cohort study PPL Fung, G Bedogni, A Bedogni, A Petrie, S Porter, G Campisi, J Bagan, ... Oral Diseases 23 (4), 477-483, 2017 | 105 | 2017 |
| Antiproliferative activity of Pt (IV)-bis (carboxylato) conjugates on malignant pleural mesothelioma cells M Alessio, I Zanellato, I Bonarrigo, E Gabano, M Ravera, D Osella Journal of Inorganic Biochemistry 129, 52-57, 2013 | 72 | 2013 |
| Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt (IV) prodrugs M Ravera, E Gabano, I Zanellato, I Bonarrigo, M Alessio, F Arnesano, ... Journal of Inorganic Biochemistry 150, 1-8, 2015 | 51 | 2015 |
| Biological activity of a series of cisplatin-based aliphatic bis (carboxylato) Pt (IV) prodrugs: how long the organic chain should be? I Zanellato, I Bonarrigo, D Colangelo, E Gabano, M Ravera, M Alessio, ... Journal of inorganic biochemistry 140, 219-227, 2014 | 46 | 2014 |
| Evaluation of platinum–ethacrynic acid conjugates in the treatment of mesothelioma I Zanellato, I Bonarrigo, M Sardi, M Alessio, E Gabano, M Ravera, ... ChemMedChem 6 (12), 2287-2293, 2011 | 35 | 2011 |
| Osteonecrosis of the jaw (ONJ) in osteoporosis patients: report of delayed diagnosis of a multisite case and commentary about risks coming from a restricted ONJ definition M Migliario, G Mergoni, P Vescovi, I De Martino, M Alessio, L Benzi, ... Dentistry journal 5 (1), 13, 2017 | 22 | 2017 |
| Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch … M Rossi, A Gambino, M Cabras, M Alessio, V Fusco Supportive Care in Cancer 29 (8), 4185-4186, 2021 | 6 | 2021 |
| Osteonecrosis of the jaws (ONJ) after bisphosphonate treatment in patients with multiple myeloma: decreasing ONJ incidence after adoption of preventive measures G Catania, F Monaco, G Limberti, M Alessio, I De Martino, C Barile, ... Dentistry Journal 4 (4), 45, 2016 | 5 | 2016 |
| Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on Marcianò et al … V Fusco, M Alessio, PF Guglielmini, M Vincenti, A Fasciolo, M Rossi International Journal of Environmental Research and Public Health 18 (19), 10143, 2021 | 4 | 2021 |
| Electrochemical Biosensor Assay of the Interaction between [PtCln(NH3)4–n](2–n) (n = 0–4) Complexes and ds‐DNA M Ravera, E Gabano, M Sardi, M Alessio, D Osella European Journal of Inorganic Chemistry 2011 (10), 1635-1639, 2011 | 4 | 2011 |
| Incidence of osteonecrosis of the jaw (ONJ) in cancer patients with bone metastases treated with bisphosphonates and/or denosumab: some comments and questions V Fusco, M Rossi, I De Martino, M Alessio, A Fasciolo, G Numico Acta Clinica Belgica 73 (2), 163-164, 2018 | 3 | 2018 |
| Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer G Ciccone, S De Luca, M Oderda, F Munoz, M Krengli, S Allis, CG Baima, ... JAMA Network Open 6 (10), e2338039-e2338039, 2023 | 1 | 2023 |
| Impact of Osteonecrosis of Jaw (ONJ) on ten year experience of a multidisciplinary osteoncology team. V Fusco, A Fasciolo, I Gallesio, M Alessio, I De Martino, L Tommasi, ... | 1 | 2021 |
| Prevention and screening of osteonecrosis of jaw (ONJ): the Alessandria experience of a multidisciplinary team on a 900-patient population. Qeios A Fasciolo, V Fusco, I De Martino, M Alessio, T Brigo, D Tartara, ... Qeios, 2021 | 1 | 2021 |
| Osteonecrosis of jaw (ONJ) with and without bone exposure in patients receiving antiangiogenic agents (+/-bisphosphonates or denosumab) V Fusco, A Fasciolo, R Gaino, D Tartara, I De Martino, M Alessio, L Benzi, ... Annals of Oncology 26, vi117, 2015 | 1 | 2015 |
| OSTEONECROSIS OF THE JAW (ONJ) IN BREAST CANCER PATIENTS: EFFECT OF PREVENTIVE MEASURES IN A MONOINSTITUTIONAL EXPERIENCE P Brigo, V Fusco, A Fasciolo, M Rossi, PF Guglielmini, D Tartara, ... | | 2021 |
| Post-COVID oncology M Rossi, G Bellotti, F Blengio, V Fusco, P Guglielmini, R Manfredi, ... Working Paper of Public Health 8 (1), 2020 | | 2020 |
| Short-term mortality among cancer patients with suspected or ascertained covid infection V Fusco, M Alessio, M Rossi, S Zai, PL Piovano, E Traverso, F Blengio, ... Tumori, 86-86, 2020 | | 2020 |
| Medication-Related Osteonecrosis of JAW (MR-ONJ) After Bisphosphonates, Denosumab and other Drugs in Advanced Cancer Patients: Recent Experience Data from Rete Oncologica … V Fusco, M Cabras, A Gambino, O Bertetto, G Numico, I De Martino, ... Annals of Oncology 28, vi90, 2017 | | 2017 |
| Osteonecrosis of jaw (ONJ) after antiresorptive treatment (bisphosphonates, denosumab) of cancer-treatment induced bone loss (CTIBL): a negligible risk? A Gambino, M Cabras, V Fusco, O Bertetto, I De Martino, M Alessio, ... Annals of Oncology 28, vi96, 2017 | | 2017 |
Domenico OsellaUniversità Piemonte Orientale UPO, DiSITEmail verificata su uniupo.it
